# US 12,109,227 B2 · Composition of matter, system, and method for enhanced magnesium uptake, retention, and synergistic actions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,109,227 B2
- Document ID: US12109227B2
- Status: Granted
- Kind: B2
- Application number: 18/331,772
- Filed: 2023-06-08
- Published: 2024-02-22
- Granted: 2024-10-08
- Earliest claimed: 2022-08-17
- Assignees: RMJH Holdings, LLC
- Applicants: RMJH Holdings, LLC
- Inventors: Russell Jaffe
- Web page: https://patentgrep.com/patent/US12109227B2

## CPC

- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/4858: {Organic compounds}
- A61K 31/131: acyclic
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides
- A61P 9/12: Antihypertensives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods and complexes for ingestion of an elemental magnesium complex as inverted micellar nanodroplets designed to enhance uptake and cell delivery of active constituents. The complex and methods associated with delivery of the elemental magnesium complex disclosed improves many magnesium deficiencies that include cardiovascular, metabolic, neurohormonal, immune defense and repair systems, digestive, behavioral, and community risks.

## Claims

### Claim 1

A method of treatment to reduce blood pressure in a hypertensive adult within 7 days comprising; administering a magnesium complex to the hypertensive adult, wherein said complex is magnesium 2-hydroxypropane-1,2,3-tricarboxylate and a quaternary amine and wherein said magnesium complex provides nanodroplets that are neutrally charged on an exterior surface of said nanodroplets and wherein within said nanodroplets there are equal negative and positive charges that stabilize said nanodroplets to provide inverted micellular nanodroplets and wherein said inverted micellular nanodroplets are disposed within tablets and/or soft gels, wherein said hypertensive adult is administered at least one first dose of said magnesium complex, wherein said at least one first dose comprises 440 mg of elemental magnesium and at least one second dose of said magnesium complex, wherein said at least one second dose comprises 440 mg of elemental magnesium so that at an end of said treatment, the seated median blood pressure is decreased in the hypertensive adult.

### Claim 2 (depends on 1)

The method of claim 1, wherein, after said treatment, the seated median blood pressure of the hypertensive adult is reduced by 5.7 mmHg.